Last reviewed · How we verify
Tranexamic Acid (TXA)
Tranexamic acid inhibits the breakdown of blood clots by blocking plasminogen activation, thereby reducing fibrinolysis and promoting clot stability.
Tranexamic acid inhibits the breakdown of blood clots by blocking plasminogen activation, thereby reducing fibrinolysis and promoting clot stability. Used for Excessive bleeding or hemorrhage (perioperative and trauma settings), Menorrhagia (heavy menstrual bleeding), Hemophilia and other bleeding disorders.
At a glance
| Generic name | Tranexamic Acid (TXA) |
|---|---|
| Also known as | TXA, Lysteda, Cyklokapron, Tranexamic acid, nebulization |
| Sponsor | NYU Langone Health |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, enzymes responsible for dissolving fibrin in blood clots. By preventing the conversion of plasminogen to plasmin, it reduces fibrinolysis (clot breakdown) and helps maintain hemostasis. This mechanism makes it useful in conditions characterized by excessive bleeding or fibrinolysis.
Approved indications
- Excessive bleeding or hemorrhage (perioperative and trauma settings)
- Menorrhagia (heavy menstrual bleeding)
- Hemophilia and other bleeding disorders
- Prevention of thromboembolic complications
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Headache
- Visual disturbances
- Hypotension
Key clinical trials
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty (NA)
- Prevention of Postpartum Hemorrhage With Tranexamic Acid (PHASE2)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit (NA)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery (EARLY_PHASE1)
- Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |